Fluxome capital
This article was originally published in The Tan Sheet
Executive Summary
Copenhagen-based biotechnology firm Fluxome Sciences secured 100 million Danish krone ($21.3 million under the July 23 conversion rates) in its latest round of financing, the firm announces July 23. Claude J. Stoufs, senior investment manager for Fluxome shareholder Capricorn Venture Partners, says he anticipates the latest capital increase will help Fluxome "become a major player in the field of nutraceutical ingredients based on production by engineered microorganisms." In June, Fluxome announced a partnership with CP Kelco U.S., a division of J.M. Huber, to develop and commercialize fermentation-derived resveratrol for the dietary supplement market, tentatively aiming for a product launch this fall...